Spyre Therapeutics, Inc.

SYRE

$2.57B

Mid Cap

NASDAQBiotechnology🇺🇸North America95 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

25w

Drug Pipeline

Drug Name	Phase	Indication	Designations
SPY002-072	Phase 2	Rheumatoid Arthritis	-
SPY001	Phase 2	Ulcerative Colitis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

SPY001 Phase 2 Results Expected

June 2026~SPY001

Primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis

Source

Phase 2

SPY002-072 Phase 2 Results Expected

Oct 31, 2026SPY002-072

Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis

Source

Regulatory Approvals

SYRE News

Spyre Therapeutics, Inc.

SYRE

$2.57B

Mid Cap

NASDAQBiotechnology🇺🇸North America95 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

25w

Drug Pipeline

Drug Name	Phase	Indication	Designations
SPY002-072	Phase 2	Rheumatoid Arthritis	-
SPY001	Phase 2	Ulcerative Colitis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

SPY001 Phase 2 Results Expected

June 2026~SPY001

Primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis

Source

Phase 2

SPY002-072 Phase 2 Results Expected

Oct 31, 2026SPY002-072

Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis

Source

Regulatory Approvals

SYRE News